pharma news today glp-1 obesity drugs Study predicts 16 new may come to market GLP-1 agonists and changes in

The half-life of approximately 12 hours with subcutaneous administration allows for flexible protocol design

The "maintained improvements" group (approximately 30-40% of users) reports substantial benefit retention 6-12 months post-discontinuation, typically characterized by users who completed 6+ month treatment courses using adequate concentrations (1-2% GHK-Cu), maintained consistent application patterns, addressed underlying skin damage during treatment allowing structural improvements, optimized complementary skincare including sun protection and moisturization, maintained healthy lifestyle supporting collagen synthesis including adequate protein intake and sleep, and possessed favorable genetics for collagen production and skin aging resistance

Causes and consequences of discontinuation of GLP1RAs or tirzepatide

This advanced therapy delivers our widest range of nutrients and antioxidants in a single infusion, designed to help support energy metabolism, immune function, skin and cellular health, and overall wellbeing